Synovial Fluid-Derived Extracellular Vesicles of Patients with Arthritides Contribute to Hippocampal Synaptic Dysfunctions and Increase with Mood Disorders Severity in Humans.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Arthritis, Rheumatoid*/diagnosis ; Extracellular Vesicles* ; Osteoarthritis*; Hippocampus ; Humans ; Mood Disorders ; Synovial Fluid

Arthritides are a highly heterogeneous group of disorders that include two major clinical entities, localized joint disorders such as osteoarthritis (OA) and systemic autoimmune-driven diseases such as rheumatoid arthritis (RA). Arthritides are characterized by chronic debilitating musculoskeletal conditions and systemic chronic inflammation. Poor mental health is also one of the most common comorbidities of arthritides. Depressive symptoms which are most prevalent, negatively impact patient global assessment diminishing the probability of achieving the target of clinical remission. Here, we investigated new insights into mechanisms that link different joint disorders to poor mental health, and to this issue, we explored the action of the synovial fluid-derived extracellular vesicles (EVs) on neuronal function. Our data show that the exposure of neurons to different concentrations of EVs derived from both RA and OA synovial fluids (RA-EVs and OA-EVs) leads to increased excitatory synaptic transmission but acts on specific modifications on excitatory or inhibitory synapses, as evidenced by electrophysiological and confocal experiments carried out in hippocampal cultures. The treatment of neurons with EVs membrane is also responsible for generating similar effects to those found with intact EVs suggesting that changes in neuronal ability arise upon EVs membrane molecules' interactions with neurons. In humans with arthritides, we found that nearly half of patients (37.5%) showed clinically significant psychiatric symptoms (CGIs score ≥ 3), and at least mild anxiety (HAM-A ≥ 7) or depression (MADRS and HAM-D ≥ 7); interestingly, these individuals revealed an increased concentration of synovial EVs. In conclusion, our data showing opposite changes at the excitatory and inhibitory levels in neurons treated with OA- and RA-EVs, lay the scientific basis for personalized medicine in OA and RA patients, and identify EVs as new potential actionable biomarkers in patients with OA/RA with poor mental health.

Ann Rheum Dis. 2019 Nov;78(11):1463-1471. (PMID: 31511227)
J Rheumatol. 2016 Feb;43(2):307-14. (PMID: 26773112)
Int J Mol Sci. 2021 Jan 29;22(3):. (PMID: 33573018)
Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20970028. (PMID: 33224281)
Eur Psychiatry. 2018 Sep;53:17-22. (PMID: 29859377)
Immunity. 2016 Apr 19;44(4):901-12. (PMID: 27096319)
J Extracell Vesicles. 2016 Nov 17;5:32570. (PMID: 27863537)
Mayo Clin Proc. 2019 Dec;94(12):2488-2498. (PMID: 31759675)
J Clin Psychopharmacol. 2008 Aug;28(4):406-10. (PMID: 18626267)
Front Oncol. 2012 Apr 17;2:38. (PMID: 22649786)
J Rheumatol. 1997 Feb;24(2):365-71. (PMID: 9034998)
PLoS Biol. 2014 Jun 03;12(6):e1001874. (PMID: 24893313)
Nat Med. 2017 Jun;23(6):714-722. (PMID: 28504723)
Clin Rheumatol. 2006 Nov;25(6):778-81. (PMID: 16609823)
Cytokine. 2007 Jun;38(3):151-6. (PMID: 17689092)
Nat Commun. 2018 Jun 8;9(1):2243. (PMID: 29884867)
Nat Rev Rheumatol. 2016 Sep;12(9):532-42. (PMID: 27411910)
Ann Rheum Dis. 2014 Jan;73(1):62-8. (PMID: 24095940)
Mediators Inflamm. 2020 Mar 3;2020:8293921. (PMID: 32189997)
Cardiovasc Diabetol. 2020 Nov 3;19(1):187. (PMID: 33143700)
Nature. 2006 Apr 20;440(7087):1054-9. (PMID: 16547515)
JCI Insight. 2021 Feb 8;6(3):. (PMID: 33373327)
Rheumatology (Oxford). 2017 Jun 1;56(6):869-881. (PMID: 27498352)
Curr Pharm Des. 2005;11(8):973-84. (PMID: 15777248)
EMBO J. 2012 Mar 7;31(5):1231-40. (PMID: 22246184)
J Affect Disord. 2015 Feb 1;172:367-74. (PMID: 25451439)
J Clin Rheumatol. 2022 Jan 1;28(1):e18-e22. (PMID: 32925449)
Cell Mol Neurobiol. 2021 Aug;41(6):1325-1336. (PMID: 32557202)
Stem Cell Res Ther. 2022 Mar 21;13(1):110. (PMID: 35313975)
Psychol Med. 2020 Nov;50(15):2526-2535. (PMID: 31576797)
Ann Rheum Dis. 2005 Jun;64(6):899-905. (PMID: 15567814)
J Neurosci. 2005 Mar 23;25(12):3219-28. (PMID: 15788779)
Lancet. 2017 Sep 16;390(10100):1211-1259. (PMID: 28919117)
Semin Arthritis Rheum. 2018 Jun;47(6):805-813. (PMID: 29157670)
Acta Neuropathol. 2018 Apr;135(4):529-550. (PMID: 29302779)
Cereb Cortex. 2016 Oct;26(10):3879-88. (PMID: 27166172)
Ann Rheum Dis. 2009 Jun;68(6):770-6. (PMID: 19297345)
Evol Med Public Health. 2019 Aug 26;2019(1):149-168. (PMID: 31548888)
Clin Exp Rheumatol. 2012 Jan-Feb;30(1):85-92. (PMID: 22325923)
Rheumatology (Oxford). 2021 Feb 1;60(2):855-865. (PMID: 32840303)
Ann Rheum Dis. 2009 Jun;68(6):777-83. (PMID: 19297344)
Rheumatology (Oxford). 2021 Apr 6;60(4):1608-1619. (PMID: 33313832)
Nat Rev Dis Primers. 2018 Feb 08;4:18001. (PMID: 29417936)
J Neurosci. 2015 Mar 25;35(12):4942-52. (PMID: 25810524)
Cell Commun Signal. 2016 Jun 10;14(1):13. (PMID: 27282631)
Lancet. 2006 Jan 7;367(9504):29-35. (PMID: 16399150)
Trends Immunol. 2006 Jan;27(1):24-31. (PMID: 16316783)
J Clin Invest. 2008 Nov;118(11):3537-45. (PMID: 18982160)
Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796)
J Geriatr Psychiatry Neurol. 2016 May;29(3):115-9. (PMID: 26392481)
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1637-41. (PMID: 12377742)
Adv Nutr. 2021 Jul 30;12(4):1149-1159. (PMID: 33427288)
Front Med (Lausanne). 2020 Dec 07;7:589079. (PMID: 33365319)
Int J Environ Res Public Health. 2021 Mar 12;18(6):. (PMID: 33809270)
Front Psychol. 2021 Aug 06;12:671768. (PMID: 34421728)
Haematologica. 2017 Sep;102(9):1594-1604. (PMID: 28596280)
Front Immunol. 2020 Dec 10;11:612104. (PMID: 33362800)
J Affect Disord. 1988 Jan-Feb;14(1):61-8. (PMID: 2963053)
Lancet Psychiatry. 2019 Feb;6(2):164-173. (PMID: 30366684)
J Immunol. 2005 Jun 1;174(11):7268-77. (PMID: 15905573)
EMBO J. 2009 Apr 22;28(8):1043-54. (PMID: 19300439)
Nat Rev Neurosci. 2008 Jan;9(1):46-56. (PMID: 18073775)
J Autism Dev Disord. 2019 Feb;49(2):773-780. (PMID: 30244391)
J Extracell Vesicles. 2018 Nov 23;7(1):1535750. (PMID: 30637094)
Brain Behav Immun. 2016 Jan;51:29-38. (PMID: 26255693)
Ann Rheum Dis. 2018 Dec;77(12):1757-1764. (PMID: 30282670)
EMBO Mol Med. 2016 Oct 4;8(10):1162-1183. (PMID: 27596437)
PLoS Biol. 2020 Mar 16;18(3):e3000643. (PMID: 32176686)
Arthritis Care Res (Hoboken). 2021 Jan;73(1):11-17. (PMID: 33026710)
BMC Psychiatry. 2021 Aug 3;21(1):385. (PMID: 34344329)
Arthritis Res Ther. 2014;16(5):470. (PMID: 25606597)
J Clin Transl Res. 2016 Sep 15;2(3):84-90. (PMID: 30873466)
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12063-E12072. (PMID: 30509997)
Depress Anxiety. 2013 Apr;30(4):297-306. (PMID: 23468190)
FASEB Bioadv. 2021 May 13;3(8):577-592. (PMID: 34377954)
RMD Open. 2017 Jul 11;3(1):e000428. (PMID: 28948983)
Osteoarthritis Cartilage. 1999 Jul;7(4):392-4. (PMID: 10419777)
Clin Exp Rheumatol. 2010 Sep-Oct;28(5):643-6. (PMID: 21029564)
Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
Brain. 2022 Mar 03;:. (PMID: 35254410)
J Neuroinflammation. 2015 Nov 25;12:223. (PMID: 26608623)
J Biol Chem. 2021 Jan-Jun;296:100089. (PMID: 33434745)
Clin Exp Rheumatol. 2010 May-Jun;28(3):300-3. (PMID: 20576224)
Brain Behav Immun. 2017 Feb;60:1-12. (PMID: 26995317)
Front Physiol. 2018 Jan 09;8:1125. (PMID: 29375397)

Keywords: EVs; neurons; osteoarthritis; rheumatoid arthritis; synaptic transmission

Date Created: 20220727 Date Completed: 20220728 Latest Revision: 20221125

20231215

PMC9331474

10.3390/cells11152276

35892573